Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Trial of Intravenous Administration of TAEK-VAC-HerBy Vaccine Alone and in Combination With HER2 Antibodies in Patients With Advanced Cancer.

NCT04246671 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.

NCT NCT04246671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04246671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Trial of Intravenous Administration of TAEK-VAC-HerBy Vaccine Alone and in Combination With HER2 Antibodies in Patients With Advanced Cancer.
Lead sponsor
Bavarian Nordic
Phase
Phase 1
Overall status
Completed
Start date
August 10, 2020
Completion date
December 11, 2024
Enrollment
37 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

chordoma, her2-positive breast cancer